Organization | South Plains Oncology Consortium

South Plains Oncology Consortium Report issue

Academic/Hospital Phase 1 Phase 2

Founded: Lubbock TX United States (2008)

Organization Overview

First Clinical Trial

2010

NCT01187810

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2017

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 2 Trials (3)

ketoconazole (nizoral) (3 trials)

n-(4-hydroxyphenyl)all-trans retinamide (5 trials)

nintedanib (ofev) (1 trial)

Drugs in Phase 1 Trials (5)

cytarabine (cytosar-u) (1 trial)

irinotecan (Camptosar) (1 trial)

naltrexone (revia) (1 trial)

safingol (1 trial)

vincristine (oncovin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Leukemia (Phase 1)

Leukemia, Lymphoid (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Lymphoma (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Neoplasms (Phase 1)

Neuroblastoma (Phase 1)

Osteosarcoma (Phase 1)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Rhabdomyosarcoma (Phase 1)

Sarcoma, Ewing (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 7
# of Trial APIs: 8